Dosing & Uses
Paroxysmal Nocturnal Hemoglobinuria
Pending FDA approval for paroxysmal nocturnal hemoglobinuria (PNH)
Next:
Pharmacology
Mechanism of Action
Novel complement C5 inhibitor that is recycled within the bloodstream, enabling sustained complement inhibition through low-dose, SC administration q4Weeks
Inhibits terminal complement-mediated intravascular hemolysis in patients with PNH
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
